NASDAQ:NBTX

Nanobiotix (NBTX) Stock Forecast, Price & News

$5.03

-0.21 (-4.01%)

(As of 06/2/2023 ET)

Compare

Today's Range: $5.00
▼
$5.15
50-Day Range: $1.98
▼
$6.68
52-Week Range: $1.75
▼
$7.76

Volume: 18,095 shs
Average Volume: 2.20 million shs
Market Capitalization: $175.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Financials Institutional Ownership Headlines SEC Filings Short Interest Social Media

About Nanobiotix (NASDAQ:NBTX) Stock

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Receive NBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter.

NBTX Stock News Headlines

June 1, 2023 | markets.businessinsider.com

Pre-market Movers: AGBA, QSG, AI, OKTA, AULT…

May 18, 2023 | finanznachrichten.de

Nanobiotix S.A.: NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

June 4, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

May 17, 2023 | msn.com

Nanobiotix reports Q1 results

May 17, 2023 | finance.yahoo.com

NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update

May 5, 2023 | seekingalpha.com

IBRX, TRUP and BAK among mid-day movers

May 5, 2023 | finance.yahoo.com

Nanobiotix Stock Triples In Trading Session: What's Going On With Stock On Friday

May 5, 2023 | markets.businessinsider.com

Nanobiotix Surges On Nearing A Contract Deal With A Major Pharma Co.

June 4, 2023 | Vector Vest (Ad)

Free Stock Analysis Report: Get Buy, Sell, or Hold Recommendation

Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.

May 5, 2023 | msn.com

Nanobiotix Soars on Potential Tie-Up with a Healthcare Major for Lead Candidate

May 5, 2023 | finance.yahoo.com

NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company

April 25, 2023 | msn.com

Why Are Nanobiotix Shares Plummeting Today?

April 25, 2023 | benzinga.com

Nanobiotix shares are trading lower after the company reported full year 2022 financial results.

April 24, 2023 | tmcnet.com

NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results

April 24, 2023 | msn.com

Earnings Scheduled For April 24, 2023

April 17, 2023 | finance.yahoo.com

NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023

March 31, 2023 | uk.finance.yahoo.com

Nanobiotix S.A. (NANO.PA)

March 30, 2023 | benzinga.com

Nanobiotix Stock (NASDAQ:NBTX), Dividends

March 29, 2023 | seekingalpha.com

Nanobiotix postpones 2022 financial results release

March 27, 2023 | finance.yahoo.com

Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call

March 27, 2023 | americanbankingnews.com

Nanobiotix (NBTX) to Release Quarterly Earnings on Tuesday

March 14, 2023 | finance.yahoo.com

Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023

December 27, 2022 | msn.com

Nanobiotix randomizes 1st patient in US in phase 3 head/neck cancer trial

December 27, 2022 | finance.yahoo.com

NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

December 21, 2022 | finance.yahoo.com

NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement

December 8, 2022 | finance.yahoo.com

Voting Rights and Shares Capital of the Company

November 15, 2022 | finance.yahoo.com

NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference

See More Headlines

NBTX Price History

30 days | 90 days | 365 days | Advanced Chart

NBTX Company Calendar

Today: 6/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NBTX
CUSIP: N/A
CIK: 1760854
Web: www.nanobiotix.com
Phone: 33-1-40-26-04-70
Fax: N/A
Employees: 98
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.38
Quick Ratio: 1.38

Sales & Book Value

Annual Sales: $5.12 million
Price / Sales: 34.27
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.82) per share
Price / Book: -6.13

Miscellaneous

Outstanding Shares: 34,880,000
Free Float: 33,673,000
Market Cap: $175.45 million
Optionable: Not Optionable
Beta: 0.08

Key Executives

Mr. Laurent Levy Ph.D. (Age 49)
Co-Founder, Pres of the Exec. Board & CEO
Comp: $585.36k

Mr. Bart Van Rhijn
CFO & Member of Exec. Board

Ms. Anne-Juliette Hermant M.A. (Age 48)
Chief People Officer & Member of Exec. Board
Comp: $304.33k

Prof. Para Prasad Ph.D. (Age 77)
Co-Founder and Member of Scientific Board

Mr. Earl J. Bergey Ph.d. (Age 67)
Co-Founder

Mr. Alain Dostie
Chief Operating Officer

Ms. Kathryn M. McNeil (Age 47)
Sr. VP of Investor Relations

Mr. Brandon Owens
VP of Strategic Marketing & Corp. Communication

Ms. Elsa Borghi
Head of Innovation & Drug Discovery

Ms. Sarah Gaubert
Head of Communication & Public Affairs Department

Key Competitors

View All Competitors

NBTX Stock - Frequently Asked Questions

How have NBTX shares performed in 2023?: Nanobiotix's stock was trading at $3.67 at the beginning of the year. Since then, NBTX shares have increased by 37.1% and is now trading at $5.03.
View the best growth stocks for 2023 here.
Are investors shorting Nanobiotix?: Nanobiotix saw a increase in short interest in May. As of May 15th, there was short interest totaling 73,200 shares, an increase of 850.6% from the April 30th total of 7,700 shares. Based on an average trading volume of 673,100 shares, the short-interest ratio is currently 0.1 days. Approximately 0.2% of the company's stock are short sold.
View Nanobiotix's Short Interest.
When did Nanobiotix IPO?: (NBTX) raised $95 million in an IPO on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont acted as the underwriters for the IPO.
What is Nanobiotix's stock symbol?: Nanobiotix trades on the NASDAQ under the ticker symbol "NBTX."

How do I buy shares of Nanobiotix?: Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Nanobiotix's stock price today?: One share of NBTX stock can currently be purchased for approximately $5.03.
How much money does Nanobiotix make?: Nanobiotix (NASDAQ:NBTX) has a market capitalization of $175.45 million and generates $5.12 million in revenue each year.
How can I contact Nanobiotix?: The official website for the company is www.nanobiotix.com. The company can be reached via phone at 33-1-40-26-04-70.

This page (NASDAQ:NBTX) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial